Heron Therapeutics Inc (NASDAQ:HRTX) reported an increase of 1.18% in shorted shares. FINRA issued shorted shares of HRTX’s total 13.94 million shares. The up change of 1.18% from 13.78 million shares was reported. 20 days will cost HRTX with 706,900 average volume to recover its former position.

HRTX is touching $25.74 during the last trading session, after increased 0.08%.Heron Therapeutics, Inc. has volume of 520,121 shares. Since March 9, 2018 HRTX has risen 35.57% and is uptrending. The stock outperformed the S&P500 by 31.20%.

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs.The company has $2.01 billion market cap. The companyÂ’s product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection.Currently it has negative earnings. It offers SUSTOL extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Ratings Coverage

In total 4 analysts cover Heron Therapeutics (NASDAQ:HRTX). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:HRTX)’s analyst reports since September 14, 2018 according to StockzIntelligence Inc. On Friday, February 22 the stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) earned “Buy” rating by Cowen & Co. On Friday, February 22 Cantor Fitzgerald maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) rating. Cantor Fitzgerald has “Buy” rating and $50 target. On Monday, February 25 Northland Capital maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) with “Buy” rating. On Friday, February 22 the firm earned “Buy” rating by Stifel Nicolaus.

For more Heron Therapeutics, Inc. (NASDAQ:HRTX) news published briefly go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Heron Therapeutics provides 2019 outlook – Seeking Alpha” published on January 07, 2019, “Heron Therapeutics: Assessing The Prospects Of An Innovator Servicing The Pain And Cancer Markets – Seeking Alpha” on June 15, 2018, “RSI Alert: Heron Therapeutics (HRTX) Now Oversold – Nasdaq” with a publish date: September 20, 2018, “Heron Therapeutics: Disrupting The Standard Of Care In Pain Management – Seeking Alpha” and the last “Heron Therapeutics Inc. (HRTX) Is Surging On FDA Priority Review – Nasdaq” with publication date: December 31, 2018.